Peptide Hydrogels for Periodontal Regeneration: When Biology Replaces the Scalpel

Periodontitis affects an estimated 47% of US adults over 30. It is the leading cause of tooth loss in adults. And the standard of care has not fundamentally changed in half a century: scale and root plane the biofilm, prescribe an antimicrobial, and if the disease progresses far enough, operate.

A June 2026 preclinical study (PMID: 42247842) describes a fundamentally different approach: deliver an endogenous pro-resolving peptide — Annexin A1 — directly into the periodontal pocket via a hydrogel scaffold. The goal is not to kill bacteria. It is to reset the host inflammatory response that causes the tissue destruction in the first place.

This is the same injectable-biologic philosophy that wound care clinicians already understand from amniotic allografts and biologic scaffolds. Now it is entering oral regenerative medicine — and periodontists, oral surgeons, and wound care clinicians tracking the biologic frontier need to understand the mechanism, the evidence, and the clinical trajectory.

---

The Periodontitis Paradigm Shift

The traditional model of periodontitis is straightforward: plaque biofilm accumulates, bacteria colonize the gingival sulcus, the host mounts an inflammatory response, and that inflammation — if unchecked — destroys the periodontal ligament and alveolar bone that support the teeth. Treatment follows logically from the model: disrupt the biofilm, reduce the bacterial load, and the inflammation will subside.

But a growing body of literature — synthesized in a comprehensive 2026 clinical practice review — argues that this model is incomplete. The bacteria are the trigger, but the host immune response is the disease. The same inflammatory mediators that drive periodontal breakdown — IL-1, IL-6, TNF-alpha — are the same mediators that drive cardiovascular disease, diabetes complications, and adverse pregnancy outcomes. Periodontitis, in the reframed view, is a systemic inflammatory disease with a local oral manifestation.

This reframing matters for treatment because it changes the therapeutic target. If excessive host inflammation — not bacterial presence — is the primary driver of tissue destruction, then the most effective intervention may not be another antimicrobial but a biologic that directly modulates the host's inflammatory cascade.

Enter Annexin A1.

---

What Is Annexin A1?

Annexin A1 (AnxA1) is a 37-kDa endogenous protein that belongs to the annexin superfamily of calcium- and phospholipid-binding proteins. It is one of the body's natural "stop signals" for inflammation — a glucocorticoid-regulated protein whose expression is upregulated during the resolution phase of the inflammatory response.

AnxA1 exerts its pro-resolving effects primarily through the formyl peptide receptor 2 (FPR2/ALX), a G-protein-coupled receptor expressed on neutrophils, macrophages, and other immune cells. The downstream effects are well-characterized across multiple inflammatory disease models:

• Neutrophil detachment and apoptosis. AnxA1 binds to FPR2/ALX on activated neutrophils, promoting their detachment from the endothelium and accelerating their programmed cell death. This stops neutrophil-mediated tissue damage at the source.
• Macrophage efferocytosis. AnxA1 stimulates macrophages to clear apoptotic neutrophils — a process called efferocytosis. This is the cellular "cleanup" that prevents secondary necrosis and drives the inflammatory response toward resolution.
• Macrophage phenotype switching. AnxA1 promotes the polarization of macrophages from the pro-inflammatory M1 phenotype (TNF-alpha, IL-1beta, reactive oxygen species) to the anti-inflammatory, pro-resolving M2 phenotype (IL-10, TGF-beta, arginase). This is the molecular switch that turns off inflammatory damage and turns on tissue repair.
• Inhibition of neutrophil recruitment. Through multiple pathways, AnxA1 reduces neutrophil adhesion to activated endothelium and their subsequent migration into tissues — the earliest step in acute inflammatory injury.

What makes AnxA1 particularly relevant to periodontitis is that the periodontal inflammatory response is characterized by precisely the processes AnxA1 resolves: persistent neutrophil infiltration, impaired efferocytosis of apoptotic neutrophils in the gingival crevice, and a macrophage population locked in the M1 phenotype.

---

The Hydrogel Delivery Challenge

The periodontal pocket is one of the most challenging drug delivery environments in the body. Constant salivary flow washes away topically applied agents within minutes. The gingival crevicular fluid — a serum transudate that increases during inflammation — creates a dynamic hydrodynamic environment. Mechanical disruption from mastication, tooth brushing, and oral movements is continuous.

Systemic administration of AnxA1 would require high doses to achieve therapeutic concentrations at the periodontal target, raising the risk of off-target immunosuppression. Local injection of free peptide into the gingival tissue is short-lived — the peptide is cleared within hours.

Hydrogel encapsulation solves both problems simultaneously.

The hydrogel described in the June 2026 study is a biocompatible scaffold designed for sustained local release. It encapsulates AnxA1 peptide within a hydrated polymer network that protects the peptide from rapid degradation and clearance. When injected into the periodontal pocket, the hydrogel:

• Adheres to the pocket epithelium through mucoadhesive interactions, resisting clearance by salivary flow
• Releases AnxA1 in a sustained manner over days to weeks, maintaining therapeutic peptide concentrations at the disease site
• Provides a physical scaffold that can support tissue infiltration and matrix deposition as inflammation resolves
• Biodegrades into non-toxic byproducts that are cleared through normal metabolic pathways

---

The Preclinical Evidence

The June 2026 study (PMID: 42247842) evaluated AnxA1 hydrogel in a ligature-induced murine periodontitis model — the gold-standard preclinical model that approximates human periodontitis by placing silk ligatures around the molars to induce biofilm accumulation and inflammatory bone loss.

Key findings:

• Reduced inflammatory cell infiltration. AnxA1 hydrogel-treated sites showed significantly fewer neutrophils and inflammatory macrophages in the gingival tissue compared to untreated and free-peptide controls, consistent with AnxA1's known mechanism of limiting neutrophil recruitment and promoting inflammatory cell clearance.
• Preserved alveolar bone. Micro-CT analysis demonstrated significantly less alveolar bone loss in animals receiving the AnxA1 hydrogel. The effect was dose-dependent — higher peptide loading in the hydrogel produced greater bone preservation.
• Enhanced tissue remodeling. Histological analysis showed that AnxA1 hydrogel-treated sites had better periodontal ligament architecture and more organized soft tissue healing. The resolution of inflammation was followed by evidence of early tissue repair.
• Biomarker confirmation. Gingival tissue lysates from treated sites showed reduced levels of pro-inflammatory cytokines (TNF-alpha, IL-1beta) and increased levels of pro-resolving mediators (IL-10, TGF-beta), confirming the predicted mechanism of action at the molecular level.

The study did not assess period pathogen levels. That is the point. The hydrogel does not kill bacteria. It modulates the host response to those bacteria — shifting from destructive inflammation to resolution and repair.

---

Clinical Context: Where AnxA1 Hydrogel Fits

The Current Host-Modulation Landscape

Host-modulation therapy is not new to periodontics. Subantimicrobial-dose doxycycline (SDD, marketed as Periostat) — 20 mg twice daily — has been FDA-approved for periodontitis for over two decades. SDD works by inhibiting matrix metalloproteinases (MMPs), particularly collagenase, that break down periodontal connective tissue during the inflammatory response.

The efficacy of SDD is modest. A 2022 Cochrane review found that adjunctive SDD produced a small additional benefit in clinical attachment level and probing depth reduction compared to scaling and root planing alone (mean difference approximately 0.2–0.3 mm). The mechanism is downstream — SDD inhibits one class of destructive enzymes but does not address the upstream inflammatory signaling that drives their production.

AnxA1 operates upstream. By acting on FPR2/ALX to reprogram the immune response at the cellular level — reducing neutrophil recruitment, promoting efferocytosis, and shifting macrophage polarization — it addresses the root cause of periodontal tissue destruction rather than one of its downstream effectors.

The Treatment Sequence

If AnxA1 hydrogel enters clinical use, the likely treatment sequence would be:

1. Diagnosis and staging. Full periodontal assessment with probing depths, clinical attachment levels, bleeding on probing, and radiographic bone height assessment.
2. Initial therapy. Scaling and root planing to disrupt the biofilm and reduce bacterial burden — the antimicrobial step remains necessary because bacteria trigger the inflammatory response even if the response itself is the destructive element.
3. Host modulation with AnxA1 hydrogel. After initial debridement, the AnxA1 hydrogel is injected into the periodontal pocket — typically the deepest pockets (≥5 mm) where inflammation-driven tissue destruction is most active.
4. Monitoring and maintenance. The patient returns at 4–8 weeks for reassessment of probing depths, bleeding scores, and clinical attachment levels. Repeat application may be indicated for persistent or recurrent pocket inflammation.

Comparison to Existing and Emerging Periodontal Biologics

Therapy	Mechanism	Stage	Key Limitation
Subantimicrobial doxycycline (Periostat)	MMP inhibition (downstream)	Approved, modest efficacy	Small clinical gains; does not address upstream inflammation
L-PRF / PRF	Growth factor release from platelet concentrates	Clinical use	Variable composition; no targeted immunomodulation
Gingiva-derived ECM hydrogel (PMID: 42183716)	ECM scaffold for soft tissue regeneration	Preclinical	Primarily structural; limited immunomodulatory activity
AnxA1 peptide hydrogel	FPR2/ALX-mediated pro-resolving signaling	Preclinical (murine)	Mechanism-specific; upstream target

---

What Clinicians Should Watch For

The June 2026 study is preclinical — murine model, proof-of-concept. The translational path to clinical use follows a defined trajectory:

• Toxicology and safety. Before first-in-human studies, GLP toxicology in a second species (typically canine or porcine) with oral administration is standard for a combination product (hydrogel + peptide). Biocompatibility per ISO 10993 for the hydrogel component is also required.
• Formulation optimization. The hydrogel formulation will need optimization for human periodontal pocket dimensions — human pockets are larger and anatomically different from murine gingival sulci. Viscosity, mucoadhesion, and release kinetics will be tuned for the human oral environment.
• First-in-human trials. A Phase 1 safety trial in chronic periodontitis patients — probably 10–30 subjects, single-arm, dose-escalation — evaluating safety, tolerability, and preliminary efficacy signals (probing depth reduction, bleeding on probing, clinical attachment gain) at 3 and 6 months.
• Combination protocols. The most clinically relevant question is how AnxA1 hydrogel performs as an adjunct to scaling and root planing compared to standard of care alone. A randomized controlled trial with the AnxA1 hydrogel group receiving the peptide after SRP, compared to SRP alone or SRP + SDD, would establish clinical utility.

---

The Bigger Picture: Injectable Biologics Meet Oral Regenerative Medicine

The AnxA1 peptide hydrogel for periodontitis is one data point in a larger pattern: the injectable-biologic paradigm — deliver a sustained biologic signal through a needle, create a regenerative microenvironment, and let host cells do the work — is expanding from wound care and orthopedics into oral regenerative medicine.

This is the same clinical philosophy NextGen Biologics has tracked across amniotic allografts for chronic wounds (inject a biologic scaffold, restart healing), injectable collagen hydrogels for cartilage repair (scaffold regeneration without surgery), and CGRP-encapsulated hydrogels for bone (all-in-one immune-vascular-osteogenic signaling). The anatomical target changes. The principle does not.

For periodontists and oral surgeons — the clinical audience evaluating biologic wound healing products every day — the AnxA1 hydrogel represents a new category of periodontal therapy: a targeted host-modulation biologic that treats inflammation as the disease, not just the consequence. The standard of care has not changed in 50 years. The science to change it has arrived.

---

Key Takeaways

1. Periodontitis affects 47% of US adults over 30, yet the standard of care — mechanical debridement + antimicrobials — has not fundamentally changed in 50 years.
2. A June 2026 study (PMID: 42247842) demonstrates that hydrogel-mediated delivery of Annexin A1 peptide — an endogenous pro-resolving agent — reduces inflammatory cell infiltration, preserves alveolar bone, and promotes tissue remodeling in a murine periodontitis model.
3. AnxA1 acts through the FPR2/ALX receptor to inhibit neutrophil recruitment, promote macrophage efferocytosis, and switch macrophages from pro-inflammatory M1 to pro-resolving M2 phenotypes — addressing the host immune dysregulation that is now recognized as the primary driver of periodontal tissue destruction.
4. Hydrogel encapsulation solves the periodontal pocket delivery problem: sustained local release in a challenging environment with constant salivary flow and mechanical disruption.
5. The treatment is preclinical, but the mechanism is well-characterized across other inflammatory disease models. Clinicians should watch for Phase 1 safety trials in chronic periodontitis, human periodontal pocket formulations, and combination studies with SRP and existing host-modulation therapies.
6. The injectable-biologic paradigm — deliver a sustained biologic signal, let host cells do the work — connects this advance to the broader class of biologic scaffolds that NextGen Biologics tracks across wound care, orthopedics, and soft tissue restoration.

---